Aims/hypothesis Glycogen accumulation occurs in beta cells of diabetic patients and has been proposed to partly mediate glucotoxicity-induced beta cell dysfunction. However, the role of glycogen metabolism in beta cell function and its contribution to diabetes pathophysiology remain poorly understood. We investigated the function of beta cell glycogen by studying glucose homeostasis in mice with (1) defective glycogen synthesis in the pancreas; and (2) excessive glycogen accumulation in beta cells. Methods Conditional deletion of the Gys1 gene and overexpression of protein targeting to glycogen (PTG) was accomplished by Cre-lox recombination using pancreasspecific Cre lines. Glucose homeostasis was assessed by determining fasting glycaemia, insulinaemia and glucose tolerance. Beta cell mass was determined by morphometry. Glycogen was detected histologically by periodic acidSchiff's reagent staining. Isolated islets were used for the determination of glycogen and insulin content, insulin secretion, immunoblots and gene expression assays. Results Gys1 knockout (Gys1 KO ) mice did not exhibit differences in glucose tolerance or basal glycaemia and insulinaemia relative to controls. Insulin secretion and gene expression in isolated islets was also indistinguishable between Gys1 KO and controls. Conversely, despite effective glycogen overaccumulation in islets, mice with PTG overexpression (PTG OE ) presented similar glucose tolerance to controls. However, under fasting conditions they exhibited lower glycaemia and higher insulinaemia. Importantly, neither young nor aged PTG OE mice showed differences in beta cell mass relative to age-matched controls. Finally, a high-fat diet did not reveal a beta cell-autonomous phenotype in either model. Conclusions/interpretation Glycogen metabolism is not required for the maintenance of beta cell function. Glycogen accumulation in beta cells alone is not sufficient to trigger the dysfunction or loss of these cells, or progression to diabetes. 
Introduction
Glycogen is a glucose polymer present mainly in liver and muscle, where it acts as an energy store. Pancreatic beta cells also express the glycogen metabolic machinery and contain detectable amounts of this polysaccharide [1, 2] . However, the precise physiological role of glycogen in beta cells remains elusive. Germ-line deletion of the glycogen synthase 1 (Gys1) gene, which codes for the enzyme responsible for the build up of glycogen in muscle and peripheral tissues, including islets and brain, results in augmented insulin secretion and improved glucose tolerance [3] , although the contribution of beta cells to this phenotype has not been established. Additionally, both a reduction in extracellular glucose and pharmacological stimulation of glycogenolysis in beta cells trigger insulin secretion in glycogen-containing islets, thereby suggesting an impact of glycogen on beta cell function [4] .
Glucotoxicity is a major contributor to beta cell loss and dysfunction and to the progression of diabetes [5, 6] . Based on the observation that glycogen accumulates in beta cells of diabetic patients and animal models of diabetes [7] [8] [9] [10] [11] , it has been proposed that glycogen metabolism partly mediates glucotoxic events by altering beta cell glucose fluxes [12] . Thus, in glycogen-rich rodent islets, glycogenolysis stimulates insulin release in the absence of extracellular glucose and, paradoxically, after a rise in glucose concentration, the glycolytic flux is reduced, resulting in decreased insulin secretion. Furthermore, pathological accumulation of glycogen has been implicated in apoptotic neuronal death in the neurodegenerative disorder known as Lafora disease [13, 14] . Likewise, glycogen overaccumulation may negatively affect beta cell survival and potentiate beta cell loss during the course of diabetes.
Here, we studied the role of glycogen in beta cell function. For this purpose, we manipulated beta cell glycogen metabolism using conditional genetic mouse models. We carried out two opposing strategies. On one hand, we generated a pancreas-specific Gys1 knockout (Gys1 KO ) model to examine the function of the polysaccharide in beta cells. On the other hand, to establish whether excessive glycogen production is detrimental for beta cell survival, we generated a transgenic model overexpressing the scaffolding protein targeting to glycogen PTG (also known as protein phosphatase 1 regulatory subunit 3C or PPP1R3C) in these cells (PTG OE model). This protein acts as a hub between glycogen synthase (GS), protein phosphatase 1 and glycogen to promote glycogen synthesis [15] . This strategy has been used to successfully enhance glycogen accumulation in several tissues [16] [17] [18] .
Methods
Animals For the generation of the Gys1 KO model, conditional Gys1 mice [19] available at our facility were crossed with Pdx1-cre (Tg[Pdx1-cre]6Tuv) mice [20] . Gys1 loxp/loxp cre −/− (WT loxp ) mice were used as controls. To drive the expression of PTG to beta cells (PTG OE model), mice conditionally expressing the coding sequence of the Ppp1r3c gene on the action of Cre recombinase [18] were crossed with rat insulin II promoter (RIP)-cre (C57BL/6-Tg[Ins2-cre]25Mgn) mice (Jackson Laboratory, Bar Harbor, ME, USA). RIP-cre mice were used as controls. All procedures were approved by the Animal Ethics/Research Committee of the University of Barcelona and carried out in accordance with the European Community Council Directive and National Institutes of Health guidelines for the care and use of laboratory animals. Mice were maintained on a 12/12 h light/dark cycle in a temperature-and humidity-controlled environment under specific pathogen-free conditions and allowed free access to water and a standard chow diet (Harlan, Indianapolis, IN, USA) or a high-fat diet (HFD) (60% energy from fat, D12492 Research Diets, New Brunswick, NJ, USA) for 16 weeks, starting at 6 weeks of age. After weaning, tail clippings were taken for genotyping (Transnetyx, Cordova, TN, USA). Animals were assigned to experiments randomly on condition of fulfilling the conditions of the experiment (genotype, sex, age). Experimenters were not blind to group assignment or outcome assessment.
Islet isolation and culture Mouse and rat pancreatic islets were isolated as described previously [21, 22] . Islets were used either fresh or after culture in RPMI medium (Sigma, St Louis, MO, USA) at 5 or 25 mmol/l glucose. Glycogen quantification Glycogen content was determined using a modification of a method described previously [25] . Briefly, 65 μl of 30% KOH was added to 50 islets (frozen in liquid nitrogen and kept at −80°C until the analysis) and heated for 15 min at 100°C. Glycogen was precipitated with cold 66% ethanol overnight, and the pellet was digested with a-amyloglucosidase. Glucose was converted into glucose 6-phosphate and measured using the fluorometric assay [26] . Note that glycogen can be underestimated in freshfrozen islets as a result of glycogen degradation during isolation.
Gene expression analysis
Histology Mice were anaesthetised and perfused intracardially with 4% paraformaldehyde. Pancreases were harvested, fixed overnight at 4°C and embedded in paraffin. For immunofluorescence, sections of 5 μm thickness were blocked in 3% donkey serum/0.5% Triton X-100, incubated overnight at 4°C with guinea pig anti-insulin (1:1,000, Dako) and mouse anti-glucagon (1:1,000, Sigma), incubated for 1 h with secondary antibodies Alexa Fluor 555 anti-mouse or anti-guinea pig (1:400, Molecular Probes), Alexa Fluor 488 anti-guinea pig or Cy2 anti-mouse (1:500, Jackson Immunoresearch, West Grove, PA, USA), and then mounted with Hoechst. Specificity of staining was validated using secondary antibodies in the absence of primary antibodies. Images were obtained using a Leica DMI 6000 B inverted microscope with a Leica DFC360 FX camera (Wetzlar, Germany). For morphometric analysis, the insulin-or glucagon-positive area was measured in four sections (at least 90 μm apart) per pancreas using ImageJ, Life-Line version (http://fiji.sc). Beta or alpha cell mass was obtained by multiplying the hormone-positive area relative to total pancreatic area by the weight of the pancreas. The insulinpositive area was divided by the number of insulin-positive cells to obtain beta cell size. Glycogen was detected histologically by periodic acid-Schiff's reagent (PAS) staining.
Metabolic tests For the i.p. GTT, mice were fasted for 16 h and injected with glucose (2 g/kg body weight for chow-dietfed mice, 1 g/kg at 8 weeks of HFD and 0.75 g/kg at 16 weeks of HFD). Glycaemia was measured in the tail vein with a glucometer (Glucocard, Arkray, Kyoto, Japan) at the indicated time points. Blood samples were taken to measure insulin using the Ultra Sensitive Mouse Insulin ELISA kit.
Statistical analysis Two-way analysis of variance was used for GTT data, and the unpaired Student's t test for other experiments. A value of p < 0.05 was considered significant. Outliers were removed when they were 2 SD from the mean. Data are expressed as mean ± SEM.
Results
Generation of a pancreas-specific Gys1 KO mouse model As an initial step, we determined the GS isoform expressed in rodent beta cells. In line with previous publications [27] , we detected Gys1 but not Gys2 (liver isoform) transcripts in mouse islets (Fig. 1a) . Correlating with the mRNA data, muscle GS but not liver GS was detected in total protein extracts from rat islets (ESM Fig. 1 ). Consequently, to study the role of glycogen metabolism in beta cell function in vivo, we sought to generate beta cell-specific (RIP-cre) Gys1 KO mice. However, no Gys1 KO mice were born, thus precluding the analysis of this model in postnatal life. Previous studies in rodents showed that glycogen infiltration in the pancreas is almost completely restricted to beta cells [10, 28] and that the glycogenic capacity of these cells is much higher than that of any other pancreatic cell type [29, 30] . We therefore undertook an alternative strategy and used a Pdx1-cre transgenic line to delete Gys1 from the whole pancreas from early embryonic stages. Pancreas-specific Gys1 KO mice were born at the expected Mendelian ratio, thus indicating that it was unlikely that failure to generate beta cell-specific Gys1 KO mice was due to beta cell-related embryonic lethality. Therefore, a more reasonable explanation would be that the cre transgene in RIP-cre mice is genetically linked to the Gys1 gene, thus impeding the inheritance of two Gys1 loxp alleles plus one copy of the cre transgene. In isolated islets from Gys1 KO mice, Gys1 mRNA was reduced by 85% and protein was undetectable by western blot (Fig. 1b-d ).
Gys1
KO mice show no metabolic alterations and have unaltered beta cell function We characterised whole-body glucose metabolism in Gys1 KO mice at 12 weeks of age. No differences were found in body weight (Fig. 2a) and, after an overnight fast, glycaemia and insulinaemia did not differ from the values of controls (Fig. 2b, c) . Glucose tolerance was unaffected in Gys1 KO mice (Fig. 2d) . To evaluate beta cell function in the absence of GS, we performed insulin secretion assays in vitro using isolated islets, which revealed no differences in insulin synthesis and in the secretory capacity of Gys1 KO islets compared with controls ( Fig. 2f) . Likewise, the expression of functionally relevant genes was unchanged in Gys1 KO islets (Fig. 2h) . Furthermore, older (45-week-old) Gys1 KO mice continued to exhibit glucose tolerance similar to that of age-matched controls (ESM Fig. 2 ). In all, these results show that glycogen metabolism is not required for adequate beta cell function and glucose homeostasis under physiological conditions.
Generation of a mouse model overexpressing PTG in beta cells To study the contribution of glycogen overaccumulation to the progression of diabetes, we generated mice overexpressing PTG specifically in beta cells (PTG OE ). Isolated pancreatic islets of this model had a 30-fold increase in mRNA levels of Ptg (also known as Ppp1r3c) (Fig. 3a ) and 3.5-fold higher glycogen levels than islets from control mice (Fig. 3b) . The latter measurement might be an underestimation because of glycogen degradation during islet isolation. In addition, PAS-positive staining confirmed increased glycogen accumulation in PTG OE mice and revealed a considerable degree of heterogeneity in the levels of glycogen among islets and individual beta cells within the same islet (Fig. 3d) . In contrast, no differences in the levels of hypothalamic glycogen were found (ESM Fig. 3) .
To determine whether glycogen stores in beta cells of PTG OE mice can be mobilised, we quantified glycogen in islets isolated from mice fasted overnight. Interestingly, glycogen levels were negligible in both groups of mice after this period (Fig. 3b) . Next, we compared glycogen accumulation in islets from PTG OE mice fed ad libitum and control islets cultured in either low (5 mmol/l) or high (25 mmol/l) glucose for 24 h. Glycogen levels were almost undetectable in both groups at 5 mmol/l glucose, while at 25 mmol/l the islets from PTG OE mice presented 6.4 times more glycogen than controls (Fig. 3c) , reaching values that were nearly three times higher than those in freshly isolated islets from fed mice. Thus, in contrast to other models of PTG overexpression [31] , glycogen accumulation in beta cells of PTG OE mice is subject to regulation and can be modulated both in vivo in response to fasting and in vitro by incubation at a range of glucose concentrations.
PTG
O E mice show fasting hypoglycaemia and hyperinsulinaemia but unaltered glucose tolerance We next assessed whether increased glycogenic capacity in beta cells from PTG OE mice resulted in alterations in whole-body glucose homeostasis. At 14 weeks of age, PTG OE mice and controls showed similar body weights (Fig. 4a) . In response to fasting, the former exhibited lower glycaemia and increased insulinaemia (Fig. 4b, c) . Despite these differences, glucose tolerance curves were comparable between groups (Fig. 4d) .
The stimulation of beta cell glycogenolysis under low glucose conditions may provide fuel to stimulate insulin secretion when glucose availability is low [32] . Hence, we assessed whether islets isolated from ad libitum-fed PTG OE mice (high glycogen levels in beta cells) showed enhanced insulin secretion under non-stimulatory conditions. Islet insulin content and insulin secretion at 2.8 and 16.7 mmol/l glucose (Fig. 4f, g ) or in response to forskolin (ESM Fig. 4) were indistinguishable between PTG OE and controls, thereby indicating that glycogen does not affect insulin production or islet secretory function. At the mRNA level, we observed no changes in the expression of genes that are essential for sustaining beta cell function (Fig. 4h) .
Glycogen accumulation is not detrimental for beta cell mass in PTG OE mice Given that both beta cell death and glycogen accumulation are observed in the course of diabetes, we addressed whether there is a causal relationship between these two events. We examined whether increased glycogen deposition in PTG OE mice affected beta cell survival. We performed morphometric quantification of beta cell area in fixed pancreases from 6-week-old mice. We did not find differences in beta cell mass, beta cell size or islet size distribution between controls and transgenic animals ( Fig. 5a-c) . Similarly, alpha cell mass was unaltered in PTG OE mice (Fig. 5d) . We considered the possibility that a detrimental effect of glycogen overaccumulation in beta cells would manifest in the long term. However, 60-week-old PTG OE mice presented no differences in beta cell mass (Fig. 5e) . Islet morphology and architecture did not show obvious alterations (Fig. 5f) . Furthermore, whole-body glucose tolerance was similar between aged PTG OE mice and controls (ESM Fig. 5 ). Therefore, sustained glycogen storage alone does not result in significant beta cell loss during normal ageing, at least at the glycogen levels reached in our PTG OE model.
An HFD does not reveal a beta cell phenotype in Gys1
KO or PTG OE mice Finally, to study whether stress conditions induce a phenotype in our transgenic models, we exposed them to an HFD. After 16 weeks of diet, Gys1 KO mice weighed more, had increased fasting glycaemia and showed a tendency towards higher insulinaemia and worsened glucose tolerance (Fig. 6a-d) . However, insulin secretory function and beta cell mass did not differ from that found in controls also on an HFD (Fig. 6e-g ). Thus, the worsened glucose tolerance of Gys1 KO mice is probably related to exacerbated insulin resistance (possibly due to hypothalamic deletion of Gys1 by expression of cre under the Pdx1 promoter [33] ) rather than to a beta cell-autonomous role. In support of this notion, after 8 weeks on an HFD, when body weights were similar between Gys1 KO and controls (Fig. 6h) , fasting glycaemia, fasting insulinaemia and glucose tolerance were indistinguishable between groups (Fig. 6i-k) . PTG OE mice fed an HFD for 16 weeks exhibited no significant differences in body weight, fasting glycaemia, insulinaemia or glucose tolerance relative to controls (Fig. 7) . 
Discussion
Here, we sought to shed new light on the long-standing debate regarding the relevance of glycogen metabolism in beta cells and the potential role of this process as a mediator of glucotoxicity, which leads to beta cell dysfunction and death. Previous studies [2, 4, 12, 32] had relied mainly on ex vivo and in vitro cellular models. Here, we used conditional genetic mouse models that exhibit impaired glycogen synthesis (Gys1 KO ) or excessive glycogen accumulation (PTG OE ) in beta cells. Our results show that the incapacity of beta cells to synthesise glycogen does not compromise whole-body glucose homeostasis or insulin secretion. Conversely, excessive glycogen accumulation in beta cells is associated with higher fasting insulin levels but not with augmented beta cell dysfunction or death under normal physiological conditions or in response to an HFD.
Pederson et al [3] showed that whole-body deletion of Gys1 in mice has a beneficial effect on glucose tolerance. This finding was attributed to increased circulating levels of insulin after a glucose challenge, which was proposed to result from enhanced glucose 6-phosphate levels and/or improved beta cell oxidative capacity. However, our data demonstrate that loss of GS does not affect insulin secretion in a beta cell-autonomous manner, thus implying that the high insulin response in constitutive Gys1 KO mice was probably secondary to alterations in other organs. In this regard, IL-6, which is more potently secreted by the muscle in conditions of low glycogen availability [34] , has been shown to stimulate insulin release through glucagon-like peptide 1 (GLP-1)-dependent [35] . Our data strongly support the notion that glycogen synthesis in beta cells is not relevant for the maintenance of proper glucose homeostasis. In contrast, our observation that exacerbated glucose intolerance of Gys1 KO mice after an HFD is associated with increased weight gain in the absence of obvious pancreatic changes points to a role of glycogen metabolism in the brain on the control of whole-body energy homeostasis. However, it is still possible that glycogen serves to fine-tune biochemical pathways and energy metabolism in beta cells. Thus, only under specific challenging situations (other than diet-induced obesity) might the inability of beta cells to synthesise glycogen have a measurable impact on beta cell function and whole-body glucose homeostasis. For instance, tissue-specific functions of glycogen have been observed in adipocytes, where it provides glycerol for triacylglycerol synthesis in the fasting to feeding transition [36] and modulates lipid metabolism after a switch from a high-fat to a standard chow diet [37] . Likewise, in neurons, glycogen has been shown to contribute to tolerance to hypoxia [38] .
In the opposite scenario, when glycogen overaccumulates in beta cells, glucose tolerance is also not affected, further supporting the minor impact of beta cell glycogen on wholebody glucose homeostasis. It should be noted that in beta cells of PTG OE mice, in contrast to other mouse models of PTG overexpression [31] , glycogen stores can be mobilised when extracellular glucose is low. In line with prior work [4] , glycogenolysis in beta cells of PTG OE mice after an overnight fast may stimulate insulin release and explain increased insulin levels when these animals are subjected to fasting. However, these differences in basal glycaemia and insulinaemia were not present when PTG OE mice received an HFD. These subtle differences may be masked by the characteristic hyperglycaemia and hyperinsulinaemia of this condition. Remarkably, basal insulin release was similar in isolated islets of PTG OE and control mice. Thus, other signals such as circulating factors or neural innervation may influence insulin release under low glucose conditions in PTG OE mice. Alternatively, temporal differences between the in vivo (16 h) and in vitro (1.5 h) assays may explain the divergence in insulin output. PTG is known to modify the phosphorylation and activity of glycogen phosphorylase [39] , resulting in reduced glycogenolytic rates [18] . It is thus plausible that the short incubation times of the in vitro insulin secretion assays precludes detection of the effects of glycogenolysis in this setting.
The PTG OE mice did not show any signs of compromised beta cell survival. We acknowledge the possibility that the amount of glycogen deposited in the islets of these animals may be below levels found in islets from diabetic counterparts and thus not be pathological. Unfortunately, because of the high post-mortem turnover of glycogen, there is no quantitative information on how much of this polysaccharide is stored in beta cells of diabetic patients. Of note, the incubation of rat islets at extremely high glucose concentration (83.3 mmol/l) [4] results in glycogen levels that are within the range stored in the islets of the PTG OE model used in the present study. It is thus reasonable to consider that these levels may represent the maximum glycogen storage capacity of beta cells (which are not 'designed' as an energy storage tissue). Alternative genetic manoeuvres, including the overexpression of GS itself, may be needed to enhance further glycogen synthesis.
In conclusion, our present data support a marginal role of beta cell glycogen in whole-body glucose homeostasis, insulin secretion and beta cell survival under physiological conditions and in response to an HFD. The availability of the genetic mouse models used in this study warrants further work to address the impact of altered glycogen metabolism in glucose homeostasis under other pathological conditions.
